Clinical Trial Update: A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial evaluating fecal microbiota transplant in combination with nivolumab for metastatic or inoperable melanoma and NSCLC; status currently UNKNOWN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Unresectable Melanoma

Drugs mentioned

• Fecal microbiota transplant (fecal microbiota transplant)
• nivolumab (nivolumab)

Snippet

Sponsor: Ella Therapeutics Ltd | Conditions: Melanoma Stage IV, Unresectable Melanoma | Phase 1, Phase 2 | Status: UNKNOWN